The US Food and Drug Administration has approved Boehringer Ingelheim’s Spirva Respimat (tiotropium bromide) inhalation spray for treating asthma. It is approved by the FDA for the long-term, once-daily, maintenance treatment of asthma in patients 12 years of age and older. Since 2014, Spirva Respimat has been approved for use in asthma in over 50 countries, including in the European Union and Japan.

Source: Boehringer Ingelheim